Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TISLELIZUMAB Cause Lymphocyte count decreased? 15 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Lymphocyte count decreased have been filed in association with TISLELIZUMAB (TEVIMBRA). This represents 0.3% of all adverse event reports for TISLELIZUMAB.

15
Reports of Lymphocyte count decreased with TISLELIZUMAB
0.3%
of all TISLELIZUMAB reports
3
Deaths
5
Hospitalizations

How Dangerous Is Lymphocyte count decreased From TISLELIZUMAB?

Of the 15 reports, 3 (20.0%) resulted in death, 5 (33.3%) required hospitalization, and 1 (6.7%) were considered life-threatening.

Is Lymphocyte count decreased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TISLELIZUMAB. However, 15 reports have been filed with the FAERS database.

What Other Side Effects Does TISLELIZUMAB Cause?

Myelosuppression (2,142) White blood cell count decreased (327) Neutrophil count decreased (277) Hepatic function abnormal (221) Pruritus (213) Rash (208) Platelet count decreased (183) Pyrexia (175) Nausea (165) Diarrhoea (145)

What Other Drugs Cause Lymphocyte count decreased?

FINGOLIMOD (3,232) DIMETHYL (960) ALEMTUZUMAB (852) CLOZAPINE (731) RITUXIMAB (633) CYCLOPHOSPHAMIDE (541) METHYLPREDNISOLONE (532) CLADRIBINE (448) DEXAMETHASONE (423) PREDNISONE (399)

Which TISLELIZUMAB Alternatives Have Lower Lymphocyte count decreased Risk?

TISLELIZUMAB vs TISOTUMAB VEDOTIN TISLELIZUMAB vs TISOTUMAB VEDOTIN-TFTV TISLELIZUMAB vs TITANIUM DIOXIDE\ZINC TISLELIZUMAB vs TIVICAY TISLELIZUMAB vs TIVOZANIB

Related Pages

TISLELIZUMAB Full Profile All Lymphocyte count decreased Reports All Drugs Causing Lymphocyte count decreased TISLELIZUMAB Demographics